Placenta Growth Factor – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)- Pipeline Review, H2 2019’, provides in depth analysis on Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Ophthalmology, Metabolic Disorders and Oncology under development targeting Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)

– The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects

– The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Alteogen Inc

Benitec Biopharma Ltd

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Cinnagen Co

Coherus BioSciences Inc

Formycon AG

Gene Techno Science Co Ltd

Huons Global Co Ltd

i2 Pharmaceuticals Inc

Lupin Ltd

Luye Pharma Group Ltd

Momenta Pharmaceuticals Inc

Oxurion NV

PharmAbcine Inc

Regeneron Pharmaceuticals Inc

Samsung Bioepis Co Ltd

Shandong Boan Biological Technology Co Ltd”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Overview

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Companies Involved in Therapeutics Development

Alteogen Inc

Benitec Biopharma Ltd

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Coherus BioSciences Inc

Formycon AG

Lupin Ltd

Momenta Pharmaceuticals Inc

Oxurion NV

Regeneron Pharmaceuticals Inc

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drug Profiles

(aflibercept + nesvacumab) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept SR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BB-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

conbercept Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-186 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-188 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THR-317 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ziv-aflibercept Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Dormant Products

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Discontinued Products

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Product Development Milestones

Featured News & Press Releases

Aug 17, 2018: FDA approves EYLEA (aflibercept) injection sBLA in wet age-related macular degeneration

Aug 13, 2018: Regeneron Provides Regulatory Update on EYLEA (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration

Aug 01, 2018: Bayer receives approval of new treatment regimen for Eylea in the EU

Jul 19, 2018: ThromboGenics Reports Day 150 Top line Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema

Jun 13, 2018: FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy

May 23, 2018: ThromboGenics to present a preclinical overview of its most advanced diabetic eye disease clinical candidate, THR-317, at EASDec 2018

May 11, 2018: Bayer receives approval for Eylea in China

Apr 27, 2018: ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combo with anti-VEGF (ranibizumab) for treatment of DME

Apr 04, 2018: ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317

Mar 20, 2018: Aflibercept shows promising data for non proliferative DR

Mar 19, 2018: EYLEA (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial

Feb 28, 2018: Regeneron Letter to Healthcare Professionals Re: EYLEA (aflibercept) Injection

Feb 13, 2018: Bayer Receives First Approval for Eylea in China

Feb 12, 2018: New data for aflibercept show prolonged injection intervals

Jan 03, 2018: Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA (aflibercept)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Alteogen Inc, H2 2019

Pipeline by Benitec Biopharma Ltd, H2 2019

Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2019

Pipeline by Cinnagen Co, H2 2019

Pipeline by Coherus BioSciences Inc, H2 2019

Pipeline by Formycon AG, H2 2019

Pipeline by Gene Techno Science Co Ltd, H2 2019

Pipeline by Huons Global Co Ltd, H2 2019

Pipeline by i2 Pharmaceuticals Inc, H2 2019

Pipeline by Lupin Ltd, H2 2019

Pipeline by Luye Pharma Group Ltd, H2 2019

Pipeline by Momenta Pharmaceuticals Inc, H2 2019

Pipeline by Oxurion NV, H2 2019

Pipeline by PharmAbcine Inc, H2 2019

Pipeline by Regeneron Pharmaceuticals Inc, H2 2019

Pipeline by Samsung Bioepis Co Ltd, H2 2019

Pipeline by Shandong Boan Biological Technology Co Ltd, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports